Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

ABSTRACT:

Background

Effective time-limited therapies remain an unmet need in chronic lymphocytic leukaemia (CLL). We evaluated a novel regimen combining ibrutinib with intermittent fludarabine, cyclophosphamide, and rituximab (FCR) in patients with CLL.

Methods

This single-arm, multicentre, phase 2 trial was conducted at three centres in China. Eligible participants were adults (aged 18-65 years) with previously untreated CLL requiring therapy according to the International Workshop on Chronic Lymphocytic Leukaemia criteria. The regimen consisted of ibrutinib (420 mg daily) combined with three cycles of FCR administered on days 1-3 of cycles 1, 5, and 9. After the completion of induction therapy, among patients who had achieved complete remission (CR) with undetectable minimal residu

SUBMITTER: Wang T 

PROVIDER: S-EPMC12766422 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature